Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Lenvima and Keytruda Combination Shows Promise in Patients with Inoperable Liver Cancer

ASCO 2020 Highlights

The combination of Lenvima (lenvatinib), an oral kinase inhibitor, and the immunotherapy Keytruda (pembrolizumab), a PD-1 inhibitor, showed promising benefits for the treatment of patients with liver cancer (or hepatocellular carcinoma) that cannot be removed by surgery (unresectable). This drug combination was also shown to be safe, according to the results of a clinical trial presented at the 2020 ASCO annual meeting by Andrew X. Zhu, MD, PhD, Director, Liver Cancer Research, Massachusetts General Hospital, Boston.

“Multi-kinase inhibition with lenvatinib plus PD-1 inhibition with pembrolizumab results in promising anti-tumor activity, as evidenced by a high objective response rate and disease control rate,” Dr. Zhu reported.

Lenvatinib is a targeted therapy that is currently approved by the FDA for the treatment of liver cancer that cannot be removed by surgery in patients who have not received any previous therapy. Pembrolizumab is an immunotherapy that is approved by the FDA for the treatment of liver cancer in patients who have already received treatment with Nexavar (sorafenib), a standard treatment for liver cancer.

Improved Outcomes

In this new study, Dr. Zhu and colleagues evaluated the efficacy and safety of the combination of lenvatinib and pembrolizumab in 100 patients with unresectable liver cancer.

According to Dr. Zhu, by the time of data collection at end of October 2019, 37 of the 100 patients in the study were still receiving treatment, including 34 patients who were receiving the 2 drugs and 3 patients who were receiving lenvatinib alone.

Almost 40% of patients were able to continue treatment with the combination of lenvatinib and pembrolizumab, which suggests that the drugs are safe and tolerable.

“Overall, there were no new or unexpected toxicities resulting from lenvatinib plus pembrolizumab combination therapy,” said Dr. Zhu.

According to the investigators, imaging tests showed that in the majority (more than 80%) of patients the tumor was shrinking, and these reductions continued for many months, between 9 months and 13 months.

In addition, treatment with this combination resulted in about 9 months of no disease progression for these patients. The percentage of patients whose tumors responded to therapy was between 36% and 46%, depending on the method used to measure a response. The disease was controlled, meaning the tumor was reduced or remained stable, in almost 90% of the patients.

Side Effects

After receiving treatment for about 8 months, almost all (95%) of the patients had at least 1 treatment-related side effect. A total of 67% of the patients had a serious (grade 3 or worse) side effect, including 63% with grade 3, 1% with grade 4 side effect, and 3 patients died. The 3 deaths were, 1 each, related to respiratory failure, abnormal liver function, and intestinal perforation (tear in the intestine).

“The most common treatment-related adverse events included hypertension, diarrhea, fatigue, decreased appetite, and hypothyroidism,” Dr. Zhu reported.

“However, most of these were grade 1 or grade 2,” he noted. Grade 1 and 2 side effects are mild and moderate and typically resolve on their own or with minimal management.

A much larger phase 3 clinical trial is currently evaluating the combination of lenvatinib plus pembrolizumab versus lenvatinib alone in patients with unresectable liver cancer. The results of this trial will provide further data on the safety and efficacy of treatment with lenvatinib plus pembrolizumab in this patient population.

Key Points

  • Treatment with lenvatinib plus pembrolizumab is safe and effective for patients with unresectable liver cancer
  • More than 80% of patients with liver cancer had tumor shrinkage, which lasted 9 to 13 months
  • Between 36% and 46% of patients’ tumors responded to the combination treatment
  • In nearly 90% of the patients, the tumor was reduced or remained stable for the length of the study period

Recommended For You